This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Veeva Systems (VEEV) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $239.53, denoting a +0.51% change from the preceding trading day.
Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 9.46% and 0.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
by Zacks Equity Research
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash
by Zacks Equity Research
Envista delivers better-than-expected top and bottom-line results for the first quarter of 2025.
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
by Zacks Equity Research
Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.
Teleflex Q1 Earnings Beat, '25 EPS View Down, Stock Up
by Zacks Equity Research
TFX benefits from a diversified product portfolio in the first quarter of 2025, with strength in the Surgical and Interventional segments.
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
by Debanjana Dey
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up
by Zacks Equity Research
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
by Zacks Equity Research
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $232.07, moving -0.69% from the previous trading session.
IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market
by Zacks Equity Research
IDEXX delivers year-over-year earnings and revenue growth in the first quarter of 2025.
ALGN Q1 Earnings and Revenues Top Estimates, Stock Up in After-market
by Zacks Equity Research
Align Technology reports first-quarter 2025 financial results, reflecting strength in the Imaging Systems & CAD/CAM Services business segment.
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 2.70% and 3.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know
by Zacks Equity Research
Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
HSIC Gears Up for Q1 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive Q1 2025 sales in each of its business segment and a positive pace of recovery from the cyber incident.
Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $227.11, moving -0.26% from the previous trading session.
CHE Stock Falls Despite Q1 Earnings & Revenue Beat, Gross Margin Declines
by Zacks Equity Research
Chemed delivers first-quarter top-line growth across two of its segments, VITAS and Roto-Rooter.
Here's Why You Should Add Veeva Stock to Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
by Zacks Equity Research
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care.
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market
by Zacks Equity Research
RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
by Zacks Equity Research
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
by Zacks Equity Research
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
by Zacks Equity Research
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.